Navigation Links
Labopharm files New Drug Submission with Health Canada for novel antidepressant
Date:8/5/2009

LAVAL, QC, Aug. 5 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced it has filed a New Drug Submission (NDS) with the Therapeutic Products Directorate of Health Canada for its novel formulation of the antidepressant trazodone.

"We are pleased to file our New Drug Submission to Health Canada," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "We believe the $800 million-plus Canadian market for antidepressants represents a significant opportunity for our trazodone formulation and we are currently in discussions with potential partners to support the commercialization of our product in Canada."

Labopharm's NDS is based on data from five pivotal pharmacokinetic studies and the positive results from a North American Phase III placebo controlled clinical trial (study 04ACL3-001), which enrolled more than 400 patients.

The eight-week randomized, double-blind, two-arm, multi-centre Phase III study in patients with major unipolar depressive disorder demonstrated the efficacy of Labopharm's formulation as a treatment for depression, as well as its positive effect on quality of sleep. The primary efficacy endpoint of the study was to compare the change in the Hamilton Rating Scale for Depression (HAMD-17) total score from baseline to the end of the study in the trazodone group versus the placebo group. Statistical significance was achieved for the primary endpoint (p value of 0.012). The majority of the secondary efficacy end points, including the HAMD-17 depressed mood item, the Clinical Global Impressions Severity (CGI-S) scale, the Montgomery Asberg Depression Rating Scale (MADRS) total score and a Responder's Analysis showed statistical significance in favor of the group administered Labopharm's trazodone. In addition, patients on Labopharm's trazodone demonstrated significant improve
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
4. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
7. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
8. FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
9. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
10. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
11. deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...wswire-FirstCall/--BostonScientificCorporation(NYS...ealthCareConference,December1-2. ,, RayElliott,...iveVicePresidentandChiefFinancialOfficer,willparti...ay,December1st,beginningatapproximately9:00a.m.E.T...etoallinterestedpartiesatBostonScientific,swebsite...
(Date:11/23/2009)....23/PRNewswire-FirstCall/--TransceptPharmaceutical...edtomeetwiththeU.S.FoodandDrugAdministration(FDA)o...egardingtheNewDrugApplication(NDA)for Intermezzo ...uslyannounced,theCompleteResponseLetter,receivedby...notapprovetheNDAinitspresentform.TheNDAseeksapprov...
(Date:11/23/2009)...23/PRNewswire-FirstCall/--Amgen(Nasdaq: AMGN )wash...PipelineandforBestNewDrugforNplate®(romiplost...lPipelineawardwaspresentedtoAmgenbyScripinrecognit...ecompany,spipeline,aswellasitsmixofcandidatesacros...elineisnotableforitsfocusonunmetclinicalneed. ,...
Breaking Medicine Technology:Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter 2Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 2Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 3Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 4Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 5Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 6Barriers Hinder EMS Workers From Using Best Resuscitation Practices 50465 1Barriers Hinder EMS Workers From Using Best Resuscitation Practices 50465 2Barriers Hinder EMS Workers From Using Best Resuscitation Practices 50465 3Barriers Hinder EMS Workers From Using Best Resuscitation Practices 50465 4U S Doctors Treat Heart Attack With Mans Own Stem Cells 50463 1U S Doctors Treat Heart Attack With Mans Own Stem Cells 50463 2FDA Advisers Urge Smaller Doses of Acetaminophen 50458 1FDA Advisers Urge Smaller Doses of Acetaminophen 50458 2FDA Advisers Urge Smaller Doses of Acetaminophen 50458 3
...s Activity in Multiple Myeloma and Mantle Cell Lym...esis,Pharmaceuticals, Inc. (Nasdaq: SNSS ) today ...in multiple myeloma and mantle cell lymphoma. Data...Multiple Myeloma Research,Consortium (MMRC) and wi...er were presented at the Annual Meeting of the Ame...
...cal data presented at the 60th Annual Meeting of t... in Chicago, SMYRNA, Ga., April 16 UCB presented...of Phase II and III double-blind, randomized,place...mide for the,treatment of diabetic neuropathic pai...nual Meeting of the American Academy of Neurology ...
Other Medicine Technology:Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research 2Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research 3Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research 4Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain 2Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain 3
(Date:11/23/2009)...ildren who don,t access health care from the same ...ntly more likely to have unmet health care needs c...blished in the journal Pediatrics . , Studies ...nd delivery of quality health care for children, t... debates about health insurance reform, much of th...
(Date:11/23/2009)...g chemo deal with insomnia, study shows , ...nd sleep disorders affect more than three-quarters...e nearly three times higher than that of the gener... is more common in younger patients and in those w...chester Medical Center researchers, who assessed s...
(Date:11/23/2009)...tyBanksin Washington D.C. , NewYorkCity , ...EconomicGrowthandRevitalization ,, WASHINGTON,...n,sleadingproviderofdialysisservices,todaywaslaude...ora$1millioninvestmentinIndustrialBankaspartofanin..., DaVita,sinvestmentinWashington,D.C.ispartofthed...
(Date:11/23/2009)...rogramSupportsFutureLeadersinSTEMFields ,, Sc...a n ceS c holars.org ,, WASHINGT...ucancountusin.Withourcommunity,foundation,andcorpo...Innovate,"saidAdolphP.Falcon,SeniorVicePresidentof...gaWhiteHousemeetingtodaywherePresidentObamaannounc...
(Date:11/23/2009).../PRNewswire-USNewswire/--SouthamptonHospitalannoun...ntofundanewEmergencyDepartment.Thegiftisthelargest...mostdoubletheexistingspaceandgreatlyexpanditsdeliv...ForkofLongIsland. ,, ScheduledforcompletionbyMa...illprovideacentralizedtraumanurses,stationandtriag...
Breaking Medicine News(10 mins):Health News:Children who lack continuity with a regular health care provider miss needed services 2Health News:Children who lack continuity with a regular health care provider miss needed services 3Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 2Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 3Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 4Health News:Alliance Joins President Obama at White House in Commitment to Science, Technology, Engineering, and Math (STEM) Education 2Health News:Southampton Hospital Receives $5 Million Gift for New Emergency Department 2
...oin Nationwide Campaign to Close the Gaps that Ma... Women of Color, SACRAMENTO, Calif., Jan. 17 Tod...ors from the seven California Affiliates of,Susan ...east cancer policies at events which included ligh...
...dge of health risks posed by long-term use , ...l phone technology and use continues to expand and...ut the potential health risks associated with long...high occupational exposure -- the report authors c...
...California premiere,of BODY WORLDS 3 & The Story o... March 14, 2008 and runs through September 7, 2008...ecimens including whole body,plastinates not seen .../DC11822 ), The Science Center hosted the US pre...
...munosyn,Corporation (OTC Bulletin Board: IMYN) ann...of of Concept Trial" for the biopharmaceutical SF-... treatment of Diabetic Ulcers., The Board of Immu...argest shareholder. Argyll Biotechnologies is the,...
...ute launched a new one-of-a-kind service for the r...ation Microarray Service (MIM) enables the rapid i...ples. The first service offering, Human Oral Micro...bacterial associations in health vs. disease, moni...
...ently discovered function of a multi-faceted trans...n both normal cells and cancer stem cells. Two sep...ary 18th issue of Molecular Cell, provide insight ...ion that is required for full activity of nuclear ...
Other Medicine News:Health News:Susan G. Komen for the Cure, State Lawmakers, Breast Cancer Survivors, Celebrities and Activists Call on Legislature to Strengthen Breast Cancer Screening Program for Underserved Women 2Health News:Susan G. Komen for the Cure, State Lawmakers, Breast Cancer Survivors, Celebrities and Activists Call on Legislature to Strengthen Breast Cancer Screening Program for Underserved Women 3Health News:Susan G. Komen for the Cure, State Lawmakers, Breast Cancer Survivors, Celebrities and Activists Call on Legislature to Strengthen Breast Cancer Screening Program for Underserved Women 4Health News:Report Urges More Research Into Cell Phones 2Health News:Report Urges More Research Into Cell Phones 3Health News:BODY WORLDS 3 & The Story of the Heart Opens at the California Science Center, March 14, 2008 2Health News:BODY WORLDS 3 & The Story of the Heart Opens at the California Science Center, March 14, 2008 3Health News:BODY WORLDS 3 & The Story of the Heart Opens at the California Science Center, March 14, 2008 4Health News:Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019 2Health News:Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019 3Health News:Forsyth launches 1-of-a-kind core service to enable rapid identification of bacterial samples 2Health News:Cancer stem cell marker also drives transcription in normal cells 2Health News:Cancer stem cell marker also drives transcription in normal cells 3
Kronos LV-T Cardiac Resynchronization Therapy Defibrillator (CRT-D) System
...Medicomps revolutionary technology provides full p...or to incorporate true Artifi cial Intelligence, w...ity, in the background, on each device. The Diogen...rdiac activity based on rate, rhythm, morphology, ...
...he new, hydrophilic PressureWire Certus guidewire ... cardiology tool for guiding intervention in patie...nal Flow Reserve (FFR)., ,Enhanced handling pr...ty with a strengthened core wire linking tip to ta...
Sound Pro Combination Table
Medicine Products: